The short answer
Cagrilintide is a long-acting analogue of amylin, the satiety hormone co-secreted with insulin. Engineered for once-weekly administration, it is the amylin component of CagriSema. Native human amylin cannot be used as a drug because it aggregates into amyloid fibrils.
Key facts
- Class
- Long-acting amylin receptor agonist
- Developer
- Novo Nordisk
- Molecular weight
- ~4,409 Da
- Molecular formula
- C194H312N54O59S2
- PubChem CID
- 171397054
- Administration
- Once weekly, subcutaneous
- Combined with
- Semaglutide, as CagriSema
- Predecessor
- Pramlintide (meal-time dosing)
The problem native amylin presents
Human amylin is a 37-residue hormone that aggregates readily into amyloid fibrils. That is not merely a formulation nuisance; it is the same process that deposits islet amyloid in type 2 diabetes. A drug that self-assembles into insoluble fibrils in the vial or at the injection site is not viable, which is why amylin analogues had to solve aggregation before they could solve anything else.
How the problem was first solved
Pramlintide, the first clinical amylin analogue, borrowed proline substitutions from rat amylin, which does not aggregate. Those substitutions disrupted the sequence's propensity to form the ordered structure amyloid requires. Pramlintide worked but had a short half-life and needed dosing with meals, which limited its practical use.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
What cagrilintide changes
Cagrilintide is engineered for once-weekly administration, which brings amylin pharmacology into the same dosing rhythm as the modern GLP-1 analogues. That matters for combination: pairing a weekly GLP-1 agonist with a meal-time amylin analogue would be impractical, whereas two weekly components can be delivered as a single fixed-dose product.
Why pair it with semaglutide at all
Amylin and GLP-1 reduce food intake through largely separate routes, amylin principally via the area postrema and GLP-1 via hypothalamic and vagal pathways. Because the pathways do not fully overlap, their effects add rather than saturate. REDEFINE 1 tested exactly this, comparing the combination against each component alone, and the combination outperformed both.
The evidence behind the combination
REDEFINE 1, in adults with obesity and without diabetes, reported 22.7% mean reduction at 68 weeks among participants who adhered and 20.4% across all randomised, against 2.3% and 3.0% on placebo respectively. REDEFINE 2, in adults with type 2 diabetes, reported 15.7% at 68 weeks against 3.1% on placebo. That is a smaller figure, which is the expected pattern in diabetic populations across the entire class.
Status
Cagrilintide is investigational as a single agent. As part of CagriSema it has been filed with the FDA. Novo Nordisk expected a decision in the fourth quarter of 2026 (report of 4 November 2026); none had been announced by 21 November 2026. It holds no MHRA authorisation.
Frequently asked questions
Is cagrilintide a GLP-1 drug?
No. It is an amylin analogue. Amylin is a separate hormone with its own receptor complex and its own satiety pathway.
Why can native amylin not be used?
It aggregates into amyloid fibrils. Clinical analogues substitute residues at the aggregation-prone positions to prevent it.
How does it differ from pramlintide?
Pramlintide is short-acting and requires dosing with meals. Cagrilintide is engineered for once-weekly administration, which makes weekly combination products possible.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubChemPubChem · Cagrilintide (CID 171397054)pubchem.ncbi.nlm.nih.gov
- RefCagriSema REDEFINE 1 results, published in NEJM. Novo Nordiskprnewswire.com
- RefNovo Nordisk files for FDA approval of CagriSemaprnewswire.com
- RefNovo Nordisk: financial report for the first nine months of 2026, 4 November 2026sec.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- What Is Exenatide? From Gila Monster Venom to MedicineExenatide is a synthetic version of exendin-4, found in Gila monster venom. Why a lizard peptide resists DPP-4 when human GLP-1 does not.
- What Is Liraglutide? The Bridge GenerationLiraglutide uses a C16 fatty acid for albumin binding, giving daily dosing. The step between exenatide and semaglutide, and what changed between them.
- Why Nausea and Efficacy Come From the Same MechanismGLP-1 slows gastric emptying and signals through the area postrema - the brainstem region governing both satiety and nausea. Why the two cannot be separated.
- Biased Agonism at the GLP-1 ReceptorTwo agonists at the same receptor can produce different outcomes by favouring cAMP over β-arrestin. Why tirzepatide internalises the receptor less than GLP-1.
- Albumin Binding and Half-Life ExtensionA fatty acid chain that binds albumin turns a peptide cleared in minutes into one dosed weekly. How chain length tunes it from liraglutide to retatrutide.